← Human Trials & Peer-Reviewed Studies
Effects of very low nicotine content cigarettes and concurrent provision of e-cigarettes on symptoms of depression and anxiety.
Plain-language guide to PMID 40965925 (2025): parallel-group randomized controlled trial of Therapeutic nicotine (patch, non-peptide).
Key Facts
- PMID
- 40965925
- Journal
- Experimental and clinical psychopharmacology
- Year
- 2025
- Study type
- Randomized Controlled Trial
- Authors
- Nolder KA et al. (14 authors)
- DOI
- 10.1037/pha0000803
What This Study Did, in Plain Language
What Was Tested
This randomized controlled trial looks at Therapeutic nicotine (patch, non-peptide).
The present study evaluated effects of cigarettes varying in nicotine content and provision of e-cigarettes on affective symptoms in populations with vulnerabilities to smoking.
This is a secondary analysis of three parallel 16-week randomized clinical trials examining four experimental conditions: normal nicotine content cigarettes, very-low-nicotine-content (VLNC) cigarettes, VLNC cigarettes plus e-cigarettes restricted to tobacco flavor (VLNC + TF), or VLNC cigarettes plus e-cigarettes in preferred flavors (VLNC + PF).
Who Took Part
By PubMed's age tags, the people studied were young adults, adults and middle-aged adults, both men and women.
How the Study Was Run
The design is described as randomized and parallel-group.
Because people in this Therapeutic nicotine (patch, non-peptide) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
The Therapeutic nicotine (patch, non-peptide) group and the comparison group ran side by side rather than switching.
What Was Measured
The present study evaluated effects of cigarettes varying in nicotine content and provision of e-cigarettes on affective symptoms in populations with vulnerabilities to smoking.
This is a secondary analysis of three parallel 16-week randomized clinical trials examining four experimental conditions: normal nicotine content cigarettes, very-low-nicotine-content (VLNC) cigarettes, VLNC cigarettes plus e-cigarettes restricted to tobacco flavor (VLNC + TF), or VLNC cigarettes plus e-cigarettes in preferred flavors (VLNC + PF).
The subject headings attached to it are Electronic Nicotine Delivery Systems, Nicotine, Depression, Anxiety and Tobacco Products.
What This Means in Plain Language
The paper is a randomized and parallel-group study of Therapeutic nicotine (patch, non-peptide).
The publication is from 2025 (Experimental and clinical psychopharmacology), a journal based in United States.
More context: the Therapeutic nicotine (patch, non-peptide) compound page, all human trials.
Our Notes on the Compound
Therapeutic nicotine (patch, non-peptide): Pure nicotine as a signaling tool, separated from smoking and vaping.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.